Brief: Creative Medical Technology Holdings Reaches Major Clinical Inflection Point With Positive Interim Data From Adapt Trial And Celz-201 (Olastrocel) In The Treatment Of Chronic Lower Back Pain
13/01/2026 14:17
Jan 13 (Reuters) - Creative Medical Technology Holdings Inc CELZ.O: CREATIVE MEDICAL TECHNOLOGY HOLDINGS REACHES MAJOR CLINICAL INFLECTION POINT WITH POSITIVE INTERIM DATA FROM ADAPT TRIAL AND CELZ-201 (OLASTROCEL) IN THE TREATMENT OF CHRONIC LOWER BACK PAIN Source text: ID:nGNX8ZvFjl Further company coverage: CELZ.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Creative Medical Technology Holdings
See all newsBrief: Creative Medical Technology Holdings Achieves Second Who Inn Milestone
Brief: Creative Medical Technology Holdings Reaches Major Clinical Inflection Point With Positive Interim Data From Adapt Trial And Celz-201 (Olastrocel) In The Treatment Of Chronic Lower Back Pain
Brief: Creative Medical Technology Receives Approval For Biodefense Burn Pit Initiative
Brief: Creative Medical Technology Completes Enrollment In FDA-Cleared Adapt Trial
Brief: Creative Medical Technology Holdings Announces World Health Organization Approval Of “Olastrocel”